Latest news
How Vertex Regained Its Footing On A Competitor's Bullish Report - Investor's Business DailyInvestor's Business Daily · Fri, 07 Aug 2026 14:50:00 GMTEquities Analysts Offer Predictions for CRSP Q3 Earnings - MarketBeatMarketBeat · Thu, 06 Aug 2026 14:36:31 GMTCRISPR Therapeutics posts 151% sales growth for CASGEVY, expands pipeline, and stays well-funded. - PluangPluang · Wed, 05 Aug 2026 19:53:17 GMTCRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 14:09:04 GMTCRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - Zacks Investment ResearchZacks Investment Research · Tue, 04 Aug 2026 14:02:19 GMTCRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - TradingViewTradingView · Mon, 03 Aug 2026 22:19:13 GMTPLTR Stock Soars After-Hours — Palantir’s 150% Commercial Revenue Growth Drives Consensus-Beating Outlook, CEO Warns Against Reliance On AI Labs - StocktwitsStocktwits · Mon, 03 Aug 2026 22:17:52 GMT